The FDA has expanded the approval of Baqsimi nasal powder to include treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

Despite consistent improvements in glycemic outcomes across simulations, real-world adoption is lagging. The study finds that ...

Hypoglycemia unawareness is when a person cannot recognize that they are experiencing an episode of low blood sugar. This can result in them losing consciousness or contribute to long-term health ...

Glargine U300 use was common, especially with increased CKD stages and baseline HbA1c levels among patients with type 2 diabetes.

The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.